In a bid to shorten clinical timelines and reduce costs, Silo Pharma plans to use the Food and Drug Administration’s streamlined 505(b)(2) regulatory pathway to push forward with its PTSD treatment. Meanwhile a Canadian patent has been granted following hot on the heels of a European patent.